Sector
Expertise

Life
Sciences

Life Sciences

For nearly two decades, we’ve assisted pharmaceutical, biotechnology, consumer health, diagnostic, digital health, and medical device organisations in attracting and developing senior executives.

Whether you are a start-up, an established corporation, or a CMO, and working on pre-clinical or clinical development, or commercialisation, we’ll help you build collaborative teams. We are skilled in customising our approach to attract diverse, globally-experienced leaders for science-driven environments.

Contact Rosalie, Practice Lead
Graphic

Key Trends in Life Sciences

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

1

Collaboration

New business models require collaborative approaches to pipeline innovation, manufacturing and supply, and myriad bench-to-bedside translations. This matrix of layered initiatives requires leaders at all levels of the organisation to be capable of cutting across traditional disciplines through influence, persuasion and compromise.

2

Precision and Personalised Medicine

The scientific advances that are giving rise to precision and personalised medicine are some of the great disruptors of our time. The radical changes that will emerge require leaders to be highly flexible, broad thinkers, who are comfortable challenging and ultimately dismantling the status quo.

3

Value-Driven Patient Access in a Limited Resource Healthcare Ecosystem

Long-term strategic planners who can realistically assess risk and make tough R&D decisions are needed to lead life science companies. They must provide value-driven access to a wide variety of customers and stakeholders in a healthcare ecosystem with limited resources, as well as develop innovative products and therapies. Alternative channels to market will be an inevitable component of any new strategy.

4

Diversity and Sustainability

Global patient demographics, emerging market demands and opportunities, and an increasingly female talent pool require inclusive leadership. Business leaders must become adept at recognising and prioritising the importance of diversity to harness its advantages for business and society.

When it comes to sustainability, we aspire to the same standards as our clients. We are proud to have been awarded a Bronze rating by Ecovadis in 2022.

5

Big Data, Digitalization, and Artificial Intelligence

Big data collection and usage; digitalization; and artificial intelligence in the entire life-cycle of therapies, from development to the point of patient access, are unstoppable trends. Wielding these technology tools in a meaningful way requires innovation leadership that is balanced by well-defined change management skills and a keen ability to prioritise.

Latest News in Life Sciences

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.

Subscribe to our Weekly Newsletter

Understanding your business is our business